Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (171-180 of 361) with videos related to

Pageof 37
Sort By:
Elife|November 16, 2022
The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progressionNehal Gupta, Hanbing Song, Wei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.
JCO Oncology Practice|January 17, 2023
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate CancerDaniel H Kwon, Kelly M Gordon, Barry Tong, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
Cancer Immunology Research|September 6, 2014
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-TDouglas G McNeel, Thomas A Gardner, Celestia S Higano, et al.
Pageof 37

Showing results (171-180 of 361) with videos related to

Sort By:
Pageof 37
Elife|November 16, 2022
The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progressionNehal Gupta, Hanbing Song, Wei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.
JCO Oncology Practice|January 17, 2023
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate CancerDaniel H Kwon, Kelly M Gordon, Barry Tong, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
Cancer Immunology Research|September 6, 2014
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-TDouglas G McNeel, Thomas A Gardner, Celestia S Higano, et al.
Pageof 37